Takamatsu H, Yagasaki H, Takahashi Y, Hama A, Saikawa Y, Yachie A, et al. Aplastic anemia successfully treated with rituximab: the possible role of aplastic anemia-associated autoantibodies as a marker for response.
This study was designed to investigate the value of tumor M2 pyruvate kinase (tumor M2-PK) determination as an early marker for response to trastuzumab therapy in patients with metastasized breast cancer.
ROS1 rearrangement can be used as a predictive marker for response to crizotinib, a tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) (Bergethon et al., 2012; Shaw et al., 2014).
Finally, CpG site No.85 can be considered as a potential marker for response to stress.
Therefore, this enzyme might be a prediction marker for response to chemotherapy.
Furthermore, the multivariate analysis revealed that RRM2 expression was an independent marker for response (P=0.002).
To date, a positive-predictive marker for response has not been defined [23].
The evidence in literature for and against Topo2 α as a marker for response to anthracyclines is variable.
Interestingly, the same studies do not support the role of TOP2A amplification as a predictive marker for response to anthracyclines.
In this particular study alphaB-crystallin was not shown to be a predictive marker for response to paclitaxel therapy.
Genomic gain for HER3 is not a marker for response or resistance to TKI therapy in advanced NSCLC patients.
